ArticleYonago acta medica2026
Near-End-of-Life Trajectory in Patients with Advanced Lung Cancer.
Article in Yonago acta medica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Performance status is a useful prognostic index in palliative care. The objectives of this study were to investigate the prognosis of near-end-of-life patients with advanced lung cancer admitted due to deteriorated performance status, evaluate the utility of performance status measurement in predicting life expectancy, and identify prognostic factors using Bayesian proportional hazards models. Methods: This prospective observational cohort study measured at admission, the Performance status, Palliative Performance Scale, Karnofsky Performance Status (KPS), Palliative Prognostic Index scores, and clinical biochemistry parameters of the included patients. Ninety-two patients with advanced lung cancer and deteriorated performance status admitted to our department at the NHO Yonago Medical Center between January 2016 and December 2018 were analyzed. Bayesian proportional hazards models were employed to classify remaining life prognoses. The Watanabe-Akaike information criteria (WAIC) with the lowest score was used to choose the final model. Results: The median survival time was 25 (range, 1-107) days. The final prognostic model for the dying trajectory of patients was selected as an M-spline proportional hazards model according to the least WAIC. Independent prognostic factors for shorter remaining life were hypercalcinemia [hazard ratio (HR) 5.37, 95% confidence interval (CI) 2.11-12.9] and low KPS (HR 1.77, 95%CI 1.30-2.46). Conclusion: Assessing hypercalcinemia and KPS can be advantageous for predicting near-end-of-life prognosis in terminally ill patients with advanced lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.